Zura Bio Limited (ZURA) Stock Score, Valuation & Financial Research

Zura Bio Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ZURA

Zura Bio Limited does not currently have a complete Wall Street Score. The stored market price is USD 3.96. These figures are a research snapshot, not a buy or sell recommendation.

What Zura Bio Limited does

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Zura Bio is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel dual-pathway antibodies for autoimmune and inflammatory diseases, relying on capital raises and strategic financing to fund its clinical-stage pipeline.

Products and services

  • The company is developing a pipeline of clinical-stage product candidates, including ZB-106 and ZB-168, targeting autoimmune and inflammatory conditions.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Lonza — The company maintains a license agreement with Lonza for which it makes annual payments. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting high unmet need in immunology Source

Business risks and research considerations

  • History of operating losses and lack of regulatory approval for any product candidates Source
  • Dependence on third-party manufacturers and clinical trial partners Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ZURA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.96
Market capitalization:
376.19M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -85.74M
Free cash flow:
USD -64.93M
Cash:
USD 205.13M
Total debt:
USD 0.00
EPS:
USD -1.13

What stands out

  • Free cash flow is USD -64.93M, negative for the stored period.
  • The balance sheet shows USD 205.13M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 205.13M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ZURA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ZURA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ZURA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ZURA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ZURA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ZURA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.